EMI 137

Drug Profile

EMI 137

Alternative Names: EMI137; GE 137

Latest Information Update: 22 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GE Healthcare
  • Developer Edinburgh Molecular Imaging; GE Healthcare; Kings College London; University Medical Center Groningen
  • Class Diagnostic agents; Imaging agents; Peptides
  • Mechanism of Action Diagnostic imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Colorectal cancer
  • Phase I/II Breast cancer; Orofacial cancer
  • Phase I Barrett's oesophagus

Most Recent Events

  • 20 Sep 2017 Edinburgh Molecular Imaging plans a clinical trials for Breast Cancer, Gastric Cancer, Thyroid Cancer, Head & Neck Cancer, Prostate Cancer and Brain Cancer (Diagnosis) in USA, United Kingdom, European Union and Asia
  • 20 Sep 2017 Phase-II clinical trials in Colorectal cancer (Diagnosis, In adults) in Netherlands (IV) (EudraCT2016-002827-27)
  • 01 Feb 2017 Phase-I clinical trials in Barrett's oesophagus (Diagnosis) in Netherlands (IV) (NCT03205501)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top